Replimune Group (REPL)
(Delayed Data from NSDQ)
$3.23 USD
-0.24 (-6.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.25 +0.03 (0.78%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REPL 3.23 -0.24(-6.79%)
Will REPL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for REPL
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty
Replimune cut to Underweight at J.P. Morgan on further headline risk
Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
Intel downgraded, Tesla upgraded: Wall Street's top analyst calls
JP Morgan Downgrades Replimune Group (REPL) to Underweight | REPL Stock News